ALCESTER

Quanta to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
Tuesday, November 9, 2021
Dialysis, ICU, Freedom, CE, Patient, Prescription, GLOBE, SC, FDA, Medical device

ALCESTER, United Kingdom and BEVERLY, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (Quanta or the Company), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today John E. Milad, Chief Executive Officer, will be participating in three upcoming investor conferences.

Key Points: 
  • ALCESTER, United Kingdom and BEVERLY, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (Quanta or the Company), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today John E. Milad, Chief Executive Officer, will be participating in three upcoming investor conferences.
  • Management will participate in investor 1x1 meetings on Tuesday, November 16 through Thursday, November 18.
  • An on-demand, pre-recorded, presentation will be made available on the conference website starting on Monday, November 22, 2021 at 10:00 a.m.
  • Headquartered in the UK and with operations in the US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.

New Quanta survey finds that one-third of UK dialysis patients still not offered the choice of home haemodialysis despite NICE guidelines for COVID

Retrieved on: 
Wednesday, October 20, 2021
Quanta, Work, National Institute for Health and Care Excellence, Risk, Dialysis, COVID-19, NICE, NHS Long Term Plan, Education, Mental health, National Institute, Self-management, Patient, HHD, Safety, Health insurance, Medicine

The survey revealed:

Key Points: 
  • The survey revealed:
    1 in 3 (34%) respondents who receive their dialysis care in-centre stated that they had not been offered the choice of HHD by their renal unit.
  • 97% of patients would recommend HHD to in-centre dialysis patients.
  • 47% of in-centre patients said they were unable to maintain social distancing and 27% of in-centre patients reported concerns about travelling to receive treatment.
  • HHD gives patients choice and flexibility around their personal dialysis schedule, enabling them to prioritise their lives and not their treatment.

New Quanta survey finds that one-third of UK dialysis patients still not offered the choice of home haemodialysis despite NICE guidelines for COVID

Retrieved on: 
Wednesday, October 20, 2021
Quanta, Work, National Institute for Health and Care Excellence, Risk, Dialysis, COVID-19, NICE, NHS Long Term Plan, Education, Mental health, National Institute, Self-management, Patient, HHD, Safety, Health insurance, Medicine

The survey revealed:

Key Points: 
  • The survey revealed:
    1 in 3 (34%) respondents who receive their dialysis care in-centre stated that they had not been offered the choice of HHD by their renal unit.
  • 97% of patients would recommend HHD to in-centre dialysis patients.
  • 47% of in-centre patients said they were unable to maintain social distancing and 27% of in-centre patients reported concerns about travelling to receive treatment.
  • HHD gives patients choice and flexibility around their personal dialysis schedule, enabling them to prioritise their lives and not their treatment.

Quanta to Present at the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021

Retrieved on: 
Tuesday, August 31, 2021
GLOBE, Dialysis, Prescription, Conference, ICU, Freedom, SC, FDA, CE, Patient, Medical device

ALCESTER, United Kingdom and BEVERLY, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (Quanta or the Company), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today John E. Milad, Chief Executive Officer, will present at the 2021 Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021, at 9:20 a.m. Eastern Time.

Key Points: 
  • ALCESTER, United Kingdom and BEVERLY, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (Quanta or the Company), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today John E. Milad, Chief Executive Officer, will present at the 2021 Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021, at 9:20 a.m. Eastern Time.
  • Headquartered in the UK and with operations in the US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.
  • The simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis.
  • Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

Quanta to Present at the LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Monday, July 19, 2021
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Hemodialysis, Dialysis, Home hemodialysis

Headquartered in the UK and with operations inthe US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.

Key Points: 
  • Headquartered in the UK and with operations inthe US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.
  • Quantas lead product, SC+, is a small and simple, powerful hemodialysis system designed to providegreater freedom and flexibility in the delivery of life sustaining dialysis treatments.
  • The simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control oftheir lives with selfcare and home dialysis.
  • Meanwhile, as a compact, portable and versatile device, SC+provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

Liberty Hall Capital Partners Appoints Kevin Vicha as Chief Executive Officer of Bromford Industries

Retrieved on: 
Monday, June 14, 2021
Bromford

CHARLESTON, S.C., BIRMINGHAM, England and ORANGE, Conn., June 14, 2021 /PRNewswire/ --Liberty Hall Capital Partners ("Liberty Hall"), a private equity firm focused exclusively on investments in businesses serving the global aerospace and defense industry, today announced the appointment of Kevin Vicha to the role of Chief Executive Officer of Bromford Industries ("Bromford"), a leading supplier of complex, close tolerance engine components, fabrications and assemblies for the global aerospace and defense and power generation industries.

Key Points: 
  • CHARLESTON, S.C., BIRMINGHAM, England and ORANGE, Conn., June 14, 2021 /PRNewswire/ --Liberty Hall Capital Partners ("Liberty Hall"), a private equity firm focused exclusively on investments in businesses serving the global aerospace and defense industry, today announced the appointment of Kevin Vicha to the role of Chief Executive Officer of Bromford Industries ("Bromford"), a leading supplier of complex, close tolerance engine components, fabrications and assemblies for the global aerospace and defense and power generation industries.
  • Bromford is now entering a new period of sustained growth, and Kevin is the right person to manage that growth," said Rowan Taylor, Liberty Hall's founding and Managing Partner.
  • Mr. Vicha added: "I am honored to take on this role and join the outstanding professionals at Bromford.
  • Liberty Hall Capital Partners is a private equity firm focused exclusively on investments in businesses serving the global aerospace and defense industry.

QUANTA Appoints Dr Selwayan Saini as Chief Operating Officer 

Retrieved on: 
Friday, February 12, 2021
Membrane technology, Detoxification, Dialysis, Quanta, Cranfield University

Alcester, Warwickshire, UK, 12 February 2021: QUANTA Dialysis Technologies Ltd (QUANTA or the Company), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces the appointment of

Key Points: 
  • Alcester, Warwickshire, UK, 12 February 2021: QUANTA Dialysis Technologies Ltd (QUANTA or the Company), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces the appointment of
    Dr Selwayan Saini as Chief Operating Officer with immediate effect.
  • Dr Saini brings with him over 15 years of experience working in senior operational roles in large global companies and in rapidly growing start-ups.
  • Dr Saini obtained his PhD from Cranfield University, a British postgraduate research university specialising in science, engineering, technology and management.
  • I would like to welcome Dr Saini to QUANTA and look forward to working with him to bring the benefits of SC+ to as many patients and healthcare professionals as possible.

QUANTA Appoints Dr Selwayan Saini as Chief Operating Officer 

Retrieved on: 
Friday, February 12, 2021
Membrane technology, Detoxification, Dialysis, Quanta, Cranfield University

Alcester, Warwickshire, UK, 12 February 2021: QUANTA Dialysis Technologies Ltd (QUANTA or the Company), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces the appointment of

Key Points: 
  • Alcester, Warwickshire, UK, 12 February 2021: QUANTA Dialysis Technologies Ltd (QUANTA or the Company), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces the appointment of
    Dr Selwayan Saini as Chief Operating Officer with immediate effect.
  • Dr Saini brings with him over 15 years of experience working in senior operational roles in large global companies and in rapidly growing start-ups.
  • Dr Saini obtained his PhD from Cranfield University, a British postgraduate research university specialising in science, engineering, technology and management.
  • I would like to welcome Dr Saini to QUANTA and look forward to working with him to bring the benefits of SC+ to as many patients and healthcare professionals as possible.

Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch

Retrieved on: 
Friday, January 8, 2021
Medicine, Membrane technology, Clinical medicine, Nephrology, Medical specialties, Renal dialysis, Quanta, Hemodialysis, Dialysis, Kidney failure

Kidney failure is one of the costliest health conditions for the American health system.

Key Points: 
  • Kidney failure is one of the costliest health conditions for the American health system.
  • This will be a pivotal year for Quanta as we build our US presence and bring our next generation hemodialysis system to a community ripe with need.
  • In preparation for commercial launch, Quanta continues to develop its US team and operations.
  • The versatility,portability and simplicity of this device, combined with amodular approach to water purification, offersomething for many different care environments.

Quanta Appoints John S. Lipman as President of North America

Retrieved on: 
Tuesday, November 24, 2020
Membrane technology, Quanta, Dialysis, ALCESTER

Alcester, Warwickshire, UK, 24 November 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British medical technology company developing innovative dialysis products and services, announces the appointment of John S. Lipman as President of North America.

Key Points: 
  • Alcester, Warwickshire, UK, 24 November 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British medical technology company developing innovative dialysis products and services, announces the appointment of John S. Lipman as President of North America.
  • John has over 25 years of leadership experience, developing and leading pre-launch and commercial companies across the medical device industry.
  • John E Milad, CEO of Quanta, said: Im delightedthat John has joined Quanta'sexecutive team.
  • Commenting on his appointment, John Lipman said: Im excited to be leading Quantas US business development and commercial activity at such an important time in the companys development.